What is the initial treatment for patent ductus arteriosus (PDA)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Treatment for Patent Ductus Arteriosus

Treatment Approach Based on Patient Population

The initial treatment for patent ductus arteriosus depends critically on whether the patient is a preterm neonate or an older child/adult, with pharmacological closure using NSAIDs (ibuprofen or indomethacin) being first-line for symptomatic preterm infants, while transcatheter device closure is the preferred initial approach for older children and adults with hemodynamically significant PDA. 1, 2


Preterm Neonates: Pharmacological Treatment

First-Line Pharmacological Agent: Ibuprofen

  • Ibuprofen is the preferred initial NSAID for PDA closure in preterm infants due to its equivalent efficacy to indomethacin but superior safety profile, particularly regarding renal function and necrotizing enterocolitis risk. 3, 4, 5

  • The recommended dosing regimen is 10 mg/kg IV initially, followed by 5 mg/kg at 24-hour intervals for two additional doses (total of 3 doses). 1

  • Oral ibuprofen is as effective as IV ibuprofen and may be preferred when feasible, with lower failure rates for PDA closure compared to IV administration. 3, 6

Alternative: Indomethacin

  • Indomethacin remains an acceptable alternative when ibuprofen is unavailable or contraindicated, though it carries higher risks of renal dysfunction (oliguria, elevated creatinine) and gastrointestinal complications. 3, 4, 7

  • Indomethacin has the unique advantage of reducing intraventricular hemorrhage risk, which ibuprofen does not provide. 4

  • Critical contraindications to indomethacin/ibuprofen include: active bleeding (especially intracranial or gastrointestinal), significant renal dysfunction, thrombocytopenia, and necrotizing enterocolitis. 1, 7

Monitoring During Pharmacological Treatment

  • Renal function must be assessed before and during treatment, monitoring for oliguria, rising creatinine, and signs of bleeding or bruising. 1, 7

  • Serial echocardiograms are essential to assess treatment response, with consideration of a second course of medical therapy if the first course fails. 1


Older Children and Adults: Transcatheter Device Closure

Device Closure as First-Line Treatment

  • Transcatheter device closure is the method of choice for PDA closure in older children and adults and should be prioritized over surgical intervention whenever technically feasible. 2, 8

  • This approach is particularly important in adults where ductal calcification and tissue friability make surgical manipulation hazardous with higher complication rates. 8, 2

Indications for PDA Closure

Closure (either percutaneously or surgically) is indicated for: 8, 2

  • Left atrial and/or left ventricular enlargement (evidence of volume overload)
  • Pulmonary arterial hypertension with net left-to-right shunting
  • Prior history of endarteritis (endocarditis)
  • Hemodynamically significant shunt (Qp:Qs >1.5)

It is reasonable to close even small asymptomatic PDAs by catheter device in older children and adults. 8, 2

Critical Contraindication

  • PDA closure is absolutely contraindicated in patients with pulmonary arterial hypertension and net right-to-left shunt (Eisenmenger physiology), as closure would be fatal. 8, 2

  • Always measure oxygen saturation in both feet and both hands to detect differential cyanosis from right-to-left shunting before proceeding with closure. 2


When Surgical Closure Becomes Necessary

Reserved for Specific Scenarios Only

Surgical closure should only be considered when device closure is not technically feasible: 8, 2

  • PDA too large for device closure

  • Distorted ductal anatomy (aneurysm, severe calcification) that precludes device placement

  • Concomitant cardiac surgery required for other indications

  • Consultation with adult congenital heart disease (ACHD) interventional cardiologists is mandatory before selecting surgical closure, especially for calcified PDAs. 8

  • When surgery is necessary, it must be performed by a surgeon experienced in congenital heart disease surgery, with success rates exceeding 95% and low early mortality. 8, 2


Conservative Management: When to Observe

Small Asymptomatic PDA

  • Routine follow-up every 3 to 5 years is appropriate for patients with small PDA without evidence of left-sided heart volume overload. 8

  • These patients require no immediate intervention but need periodic echocardiographic surveillance to detect development of hemodynamic significance. 8


Common Pitfalls to Avoid

  • Never close a PDA in the presence of Eisenmenger physiology (right-to-left shunt with severe pulmonary vascular disease), as this will cause acute right heart failure and death. 8, 2

  • Do not use indomethacin or ibuprofen in late pregnancy as these agents can cause premature closure of the fetal ductus arteriosus. 7

  • Avoid assuming all continuous murmurs represent hemodynamically insignificant PDAs—when pulmonary hypertension develops, the continuous murmur may disappear and only a systolic component remains. 9

  • In preterm infants, prophylactic indomethacin increases initial constriction rates but does not prevent reopening in the most immature infants, so post-treatment echocardiography is essential to confirm closure. 10

References

Guideline

Patent Ductus Arteriosus Management in Children

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Patent Ductus Arteriosus Closure Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of patent ductus arteriosus: indomethacin or ibuprofen?

Journal of perinatology : official journal of the California Perinatal Association, 2008

Research

Treatment of patent ductus arteriosus with ibuprofen.

Archives of disease in childhood. Fetal and neonatal edition, 1997

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

PDA Classification and Diagnosis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.